Current applications of pharmacovigilance in medications during pregnancy

doi:10.19803/j.1672-8629.2022.03.10

Abstract

Abstract: Objective To explore the current applications of pharmacovigilance in drug therapies during pregnancy. Methods The developments of pharmacovigilance in different countries and regions were summarized. The characteristics of common medications in pregnant populations were analyzed. According to the characteristics of safe medications during pregnancy, the related adverse reactions were investigated, the patterns of safe medications were explored, and the applications of pharmacovigilance during pregnancy were discussed. Finally, suggestions for improving pharmacovigilance during pregnancy were offered. Results In recent years, pharmacovigilance at home and abroad developed rapidly in order to better evaluate drug safety and guide clinical use. Different countries and regions established corresponding pharmacovigilance systems. The pregnant were a special medication group. Due to various needs, medications were common during pregnancy. Changes in the physiological and psychological status of pregnant women during could directly affect the efficacy of medications. The incidence of adverse drug reactions after medication during pregnancy was high. Conclusion Attention should be paid to the safety of medications during pregnancy and more effective pharmacovigilance systems during pregnancy should be established.

Key words: pharmacovigilance, pregnancy, drug therapy

CLC Number:

R969.3

LU Yanan, BAI Ruixue, YANG Yuehui. Current applications of pharmacovigilance in medications during pregnancy[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 279-282.

References

[1] DATHE K, SCHAEFER C.The use of medication in pregnancy[J].Deutsches Arzteblatt International, 2019, 116(46): 783-790.
[2] VOLQVARTZ T, VESTERGAARD A, AAGAARD S, et al.Use of alternative medicine, ginger and licorice among Danish pregnant women-a prospective cohort study[J]. BMC Complementary and Alternative Medicine, 2019, 19(1): 5-14.
[3] ZENG FD.Pharmacovigilance and clinical pharmaceutical care[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2014, 23(12): 718-721.
[4] PENG LL, WANG D, SHEN L, et al.The origin and development of pharmacovigilance[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(7): 410-413.
[5] HUANG GH, DU HR, GONG LK.Analysis of research situation in the international field of pharmacovigilance in the past five years and its enlightenment to my country[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(5): 268-275.
[6] LI DJ.An introduction to the WHO Uppsala Monitoring Center and the Swedish drug alert system and its enlightenment to the above[J]. Shanghai Food and Drug Information Research(上海食品药品监管情报研究), 2012, 3: 1-5.
[7] LI J, WANG J.Med watch-adverse drug reaction reporting program on FDA website[J]. Progress in Pharmaceutical Sciences(药学进展), 2001, 25(2): 108-110.
[8] SONG L, ZHANG BK.Introduction to the pharmacovigilance system in the United States and France and its enlightenment to my country[J]. China Pharmacy(中国药房), 2009, 20(14): 1043-1045.
[9] ZHU XY, ZHANG WG, SUN SS, et al.The development of pharma-covigilance and bibliometric analysis in China[J]. Herald of Medicine(医药导报), 2019, 38(6): 820-825.
[10] LIU PC, CHEN JM, YAO WB.Thoughts on China's pharmac-ovigilance system under the new coronavirus pneumonia epidemic[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(7): 389-392, 398.
[11] CHEN HQ, WANG ZL, ZOU SH, et al.Investigation on drug use during pregnancy[J]. Chinese Journal of Perinatal Medicine(中华围产医学杂志), 2014, 17(5): 351-353.
[12] World Health Organization.The Importance of pharmac-ovigilance[M]. WHO Library: The United Kingdom, 2002.
[13] BÉRARD A, ABBAS-CHORFA F, KASSAI B, et al. The French pregnancy cohort: medication use during pregnancy in the French population[J]. PLoS One, 2019, 14(7): 1-18.
[14] DE WAARD M, BLOMJOUS B, HOL M, et al.Medication use during pregnancy and lactation in a dutch population[J]. Journal of Human Lactation: Official Journal of International Lactation Consultant Association, 2019, 35(1): 154-164.
[15] YANG Y, CHEN C, LIU XX.Pharmacokinetic characteristics and drug safety of pregnancy drugs in the mother and fetus[J]. Herald of Medicine(医药导报), 2017, 36(9): 951-955.
[16] SPAAN J, BROWN M.Can we protect the kidneys after hypertensive pregnancy?[J]. CMAJ: Canadian Medical Association Journal, 2013, 185(3): 199-200.
[17] MA YY, MA LJ, GAO LX.Characteristics of drug metabolism during pregnancy and lactation[J]. Chinese Journal of Practical Gynecology and Obstetrics(中国实用妇科与产科杂志), 2008, 24(6): 462-464.
[18] GLANTZ A, MARSCHALL H, MATTSSON L.Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates[J]. Hepatology, 2004, 40(2): 467-474.
[19] LIAO ML, FANG F, LIU GX, et al.Influencing factors and correlation of anxiety, psychological stress sources, and psychological capital among women pregnant with a second child in Guangdong and Shandong Province[J]. Journal of Affective Disorders, 2020, 264: 115-122.
[20] QIN SX, TAN YP, LU BY, et al.Survey and analysis for impact factors of psychological distress in HIV-infected pregnant women who continue pregnancy[J]. The Journal of Maternal-Fetal & Neonatal Medicine, 2019, 32(19): 3160-3167.
[21] HOUBEN E, TE WINKEL B, STEEGERS E, et al.Dutch trends in the use of potentially harmful medication during pregnancy[J]. British Journal of Clinical Pharmacology, 2020, 2: 1-16.
[22] DA SILVA K, FERNANDES F, DE LIMS PESSOA T, et al. Prevalence and profile of adverse drug reactions in high-risk pregnancy: a cohort study[J]. BMC Pregnancy and Childbirth, 2019, 199(1): 199-204.
[23] DA COSTA T, DE ALMEIDA PIMENTA CUNHA M, DO VALE BEZERRA P, et al. Incidence of adverse drug reactions in high-risk pregnancy: a prospective cohort study in obstetric intensive care[J]. European Journal of Clinical Pharmacology, 2020, 76(2): 291-298.
[24] DE OLIVEIRA-FILHO A, VIEIRA A, DA SILVA R, et al. Adverse drug reactions in high-risk pregnant women: a prospective study[J]. Saudi Pharmaceutical Journal, 2017, 25(7): 1073-1077.
[25] BENEVENT J, ARAUJO M, HURAULT-DELARUE C, et al.Pharmacoepid-emiology in pregnancy[J]. Therapie, 2019, 74(2): 289-300.
[26] DU BR, FENG X, SHI XJ.The implementation and impact of the US FDA's new drug use rules for pregnant women[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2016, 51(12): 1049-1054.
[27] SAHIN L,NALLANI SC,TASSINARI MS.Medication use in pregnancy and the pregnancy and lactation labeling rule[J]. Clinical Pharmacology and Therapeutics, 2016, 100(1): 23-25.
[28] HELLWIG K, DUARTE CARON F, WICKLEIN EM, et al.Pregnancy outcomes from the global pharmacovigilance database on interferon beta-1b exposure[J]. Therapeutic Advances in Neurological Disorders, 2020, (13): 1-11.
[29] BEEX-OOSTERHUIS MM, SAMB A, HEERDINK ER, et al.Safety of clozapine use during pregnancy: analysis of international pharmacovigilance data[J]. Pharmacoepidemiology and Drug Safety, 2020, 29(6): 725-735.
[30] ONKEN M, MICK I, SCHAEFER C.Paliperidone and pregnancy-an evaluation of the German embryotox database[J]. Arch Womens Ment Health, 2018, 21(6): 657-662.
[31] DANET C,ARAUJO M, BOS-THOMPSON MA, et al.Pregnancy outcomes in women exposed to cancer chemotherapy[J]. Pharm-acoepidemiology and Drug Safety, 2018, 27(12): 1302-1308.
[32] ZHOU W, LIU AL, DU GH.Comparative study on adverse drug reaction monitoring systems between China and the United Kingdom[J]. Chinese Journal of Drug Evaluation, 2015, 32(6): 376-380.